“Somerset Therapeutics Atropine Sulfate Ophthalmic Solution Recall: Impurities Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/32361-somerset-therapeutics-atropine-sulfate-ophthalmic-solution-recall-impurities-risk. Based on FDA recall #D-0169-2025 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0169-2025%22&limit=1).
Somerset Therapeutics LLC voluntarily recalled Atropine Sulfate Ophthalmic Solution, USP 1%, in 5 mL bottles nationwide on Dec. 16, 2024, due to failed impurity specifications, the FDA said. The recall affects 5,870 units distributed across the United States.
How to tell if you have it
Brand: Somerset Therapeutics
Product: Atropine Sulfate Ophthalmic Solution, USP 1%, 5 mL bottles
NDC: 70069-716-01
Lot #: A240211
Exp. Date: April 2026
The hazard
The product failed impurity specifications because out-of-specification results were observed during long-term stability testing at product expiry, according to the FDA. The recall is classified as Class III.
Context
GovInfoNow's records show Somerset Therapeutics LLC has four other recalls on record since June 4, 2020. Other recent recalls of similar products include a Dexamethasone Injection recall (Feb. 4, 2026), a Cisatracurium Besylate Injection recall (Nov. 26, 2025), and a Haloperidol Injection recall (April 24, 2024). Other recent recalls of similar products include a Fluocinolone Acetonide Solution recall (Dec. 30, 2025), a Clindamycin Phosphate Topical Solution recall (Nov. 26, 2025), and an Atropine Sulfate Injection recall (July 24, 2026).
How to tell if you have this one
Check for the NDC code 70069-716-01 and lot number A240211 on the bottle label. The product is only available by prescription and comes in 5mL bottles.
Brand
Somerset Therapeutics
Category
Drug
Based on the official FDA remedy
What to do — step by step
Check Product Details
Look for NDC 70069-716-01 and lot A240211 on the bottle label.
Where it went and when
Where it was distributed
Distributed nationwide.
Nationwide
Not listed
FDA distribution: “Nationwide within the United States” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 6 months after the firm started it.
1Firm started the recall
2FDA classified it Class III
3Published in FDA’s Enforcement Report
4FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
Official source: FDA Recall #D-0169-2025 (December 16, 2024) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0169-2025 to see it in context.
Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.